Below are the most recent publications written about "Cystatin C" by people in Profiles.
-
Yan G, Nee R, Scialla JJ, Greene T, Yu W, Cheung AK, Norris KC. Estimation of Black-White Disparities in CKD Outcomes: Comparison Using the 2021 Versus the 2009 CKD-EPI Creatinine Equations. Am J Kidney Dis. 2022 09; 80(3):423-426.
-
Rizk JG, Streja E, Wenziger C, Shlipak MG, Norris KC, Crowley ST, Kalantar-Zadeh K. Serum Creatinine-to-Cystatin-C Ratio as a Potential Muscle Mass Surrogate and Racial Differences in Mortality. J Ren Nutr. 2023 Jan; 33(1):69-77.
-
McClean M, Buzkova P, Budoff M, Estrella M, Freiberg M, Hodis HN, Palella F, Shikuma C, Post WS, Gupta S. Brief Report: Cystatin C-Based Estimation of Glomerular Filtration Rate and Association With Atherosclerosis Imaging Markers in People Living With HIV. J Acquir Immune Defic Syndr. 2020 12 01; 85(4):466-469.
-
Premeaux TA, Javandel S, Hosaka KRJ, Greene M, Therrien N, Allen IE, Corley MJ, Valcour VG, Ndhlovu LC. Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy. Front Immunol. 2020; 11:1321.
-
Holloway AJ, Yu J, Arulanandam BP, Milligan GN, Eaves-Pyles TD. Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2019 05; 63(5).
-
Holloway AJ, Yu J, Arulanandam BP, Hoskinson SM, Eaves-Pyles T. Cystatins 9 and C as a Novel Immunotherapy Treatment That Protects against Multidrug-Resistant New Delhi Metallo-Beta-Lactamase-1-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 03; 62(3).
-
Wilder CL, Walton C, Watson V, Stewart FAA, Johnson J, Peyton SR, Payne CK, Odero-Marah V, Platt MO. Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells. Int J Biochem Cell Biol. 2016 10; 79:199-208.
-
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, Bart BA, Bull DA, Stehlik J, LeWinter MM, Konstam MA, Huggins GS, Rouleau JL, O'Meara E, Tang WH, Starling RC, Butler J, Deswal A, Felker GM, O'Connor CM, Bonita RE, Margulies KB, Cappola TP, Ofili EO, Mann DL, D?vila-Rom?n VG, McNulty SE, Borlaug BA, Velazquez EJ, Lee KL, Shah MR, Hernandez AF, Braunwald E, Redfield MM. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310(23):2533-43.
-
Rodriguez-Franco EJ, Cantres-Rosario YM, Plaud-Valentin M, Romeu R, Rodr?guez Y, Skolasky R, Mel?ndez V, Cadilla CL, Melendez LM. Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis. PLoS One. 2012; 7(5):e36571.
-
Bhavsar NA, Appel LJ, Kusek JW, Contreras G, Bakris G, Coresh J, Astor BC. Comparison of measured GFR, serum creatinine, cystatin C, and beta-trace protein to predict ESRD in African Americans with hypertensive CKD. Am J Kidney Dis. 2011 Dec; 58(6):886-93.